Innoviva, Inc. (NASDAQ: INVA)

Innoviva, Inc. is a healthcare company focused on generating value from its core royalties portfolio, a critical care and infectious disease platform, and strategic investments in healthcare assets. The company’s primary business involves earning royalties from respiratory products developed in collaboration with GSK, commercializing its own portfolio of critical care and infectious disease therapeutics, and maintaining equity stakes in other healthcare companies to drive long-term value. Innoviva operates at the intersection of pharmaceutical royalties, specialty therapeutics, and strategic capital allocation within the healthcare sector.

Innoviva generates revenue through three primary streams: royalty income from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, net product sales from its marketed critical care and infectious disease portfolio, and license revenue from collaboration agreements. The royalty stream provides a recurring income stream based on global sales of Fluticasone Furoate/Vilanterol and Umeclidinium Bromide/Vilanterol combinations. Net product sales derive from U. S. and international sales of GIAPREZA® (angiotensin II) for septic shock, XACDURO® (sulbactam-durlobactam) for hospital-acquired bacterial pneumonia, XERAVA® (eravacycline) for complicated intra-abdominal infections, and ZEVTERA® (ceftobiprole) for bloodstream infections, skin infections, and community-acquired bacterial pneumonia. License revenue arises from milestone and development-based payments under agreements such as the Amended Zai Agreement with Zai Lab.

The company operates through the following segments: Innoviva Specialty Therapeutics (IST), Royalty Portfolio, and Strategic Investments.

• Innoviva Specialty Therapeutics (IST) is the commercial and development platform focused on critical care and infectious disease therapeutics. It markets and sells GIAPREZA®, XACDURO®, XERAVA®, and ZEVTERA® in the United States and select international markets. IST also advances the clinical development of zoliflodacin, a potential first-in-class oral single-dose treatment for uncomplicated gonorrhea, in partnership with GARDP. The segment includes regulatory, commercial, and medical affairs functions supporting product launch, market access, and lifecycle management.

• The Royalty Portfolio consists of the long-acting beta2 agonist (LABA) collaboration with GSK, under which Innoviva receives tiered royalties on global net sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Specifically, Innoviva earns 15% on the first $3.0 billion of annual global net sales and 5% on sales above that threshold for RELVAR®/BREO® ELLIPTA®, and a tiered royalty rate ranging from 6.5% to 10% on ANORO® ELLIPTA® sales. This portfolio requires no ongoing commercialization investment from Innoviva, as GSK handles manufacturing, distribution, and marketing.

• Strategic Investments encompass Innoviva’s equity stakes and financial interests in other healthcare companies. Notable among these is a significant ownership position in Armata Pharmaceuticals, a bacteriophage-focused therapeutics company developing treatments for serious infections including Staphylococcus aureus bacteremia. Innoviva also holds investments in companies such as InCarda Therapeutics, Gate Bio, ImaginAb, Syndeio, and Beacon Biosignals, as well as interests managed through ISP Fund LP. These investments are made to capitalize on innovation in adjacent therapeutic areas and generate financial returns through appreciation or strategic exits.

Innoviva holds a distinctive position in the healthcare industry due to its dual-model approach combining royalty-generating assets with active commercialization and strategic investing. Unlike traditional pharmaceutical companies that rely solely on internal R&D and sales, Innoviva de-risks revenue through GSK-partnered respiratory royalties while leveraging its IST platform to commercialize differentiated anti-infective agents. Its competitors in the royalty space include companies like Royalty Pharma and Immunovant, while in the critical care and infectious disease arena, it faces competition from larger specialty pharmaceutical firms such as Melinta Therapeutics, Cidara Therapeutics, and Merck & Co. Innoviva’s competitive advantages include its low-cost royalty stream, focused expertise in hospital-acquired infections and antimicrobial resistance, and disciplined capital allocation toward high-potential biotech opportunities.

Innoviva serves healthcare providers and institutions, primarily hospitals, health systems, and clinicians specializing in critical care, infectious disease, and pulmonology. Its products GIAPREZA®, XACDURO®, XERAVA®, and ZEVTERA® are used in acute care settings to treat life-threatening conditions such as septic shock, ventilator-associated pneumonia, complicated intra-abacterial infections, and bacterial bloodstream infections. The company’s respiratory royalty products are used by patients with asthma and chronic obstructive pulmonary disease (COPD) worldwide, distributed through GSK’s global commercialization network. Innoviva does not sell directly to patients but relies on institutional formularies, group purchasing organizations, and wholesale distributors to reach end users.